Buy the stock on weakness. That’s the advice from Raymond James analyst Michael W. Freeman on Profound Medical Corp. (Profound Medical Stock Quote, Chart, News, Analysts, Financials NASDAQ:PROF). “Here we address recent weakness in PROF stock and highlight catalysts to expect through 2025,” the analyst wrote. “PROF was down (18%) vs. Nasdaq (0.2%) since the […]
Medexus could be a five-bagger, Raymond James saysAn FDA approval could send one Canadian-listed stock flying, says Raymond James analysts Michael W. Freeman. In a research update to clients January 7, the analyst upgraded Medexus Pharmaceuticals (Medexus Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials TSX:MDP) from “Outpeform 2” to “Strong Buy 1”, while maintaining his one-year price target of $4.00 on the […]